FDC

Sector: Biotechnology & Drugs
Powered by
262.30 -0.55 (-0.21%)
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y

Price Range

Today’s Low 260.2
Today’s High 267.75
52 Week Low 229.15
52 Week High 366.0

Key Metrics

  • Market Cap (In Cr) 4352.65
  • Beta 0.64
  • Div. Yield (%) 0
  • P/B 2.26
  • TTM P/E 21.23
  • Peg Ratio 0.28
  • Sector P/E 24.66
  • D/E -
  • Open Price 264.15
  • Prev Close 262.85
View All Metrics on Mint Genie

Analysis

Price Analysis
  • 1 Week
    -5.58%
  • 3 Months
    9.93%
  • 6 Month
    2.04%
  • YTD
    -13.76%
  • 1 Year
    -25.33%
Risk Meter
  • 26% Low risk
  • 26% Moderate risk
  • 26% Balanced Risk
  • 26% High risk
  • 26% Extreme risk
Recos
1 Analysts
  • Strong Sell
  • Sell
  • Hold
  • Buy
  • Strong Buy
Analysts' Views
  • Ratings
  • Current
  • Strong Sell
  • 0
  • Sell
  • 0
  • Hold
  • 0
  • Buy
  • 0
  • Strong Buy
  • 1

Financials

  • INCOME
  • BALANCE SHEET
  • Cashflow
  • Period
  • 2022
  • Total Revenue
  • 1527.92
  • Selling/ General/ Admin Expenses Total
  • 642.69
  • Depreciation/ Amortization
  • 37.3
  • Other Operating Expenses Total
  • 15.24
  • Total Operating Expense
  • 1311.53
  • Operating Income
  • 216.38
  • Net Income Before Taxes
  • 289.39
  • Net Income
  • 216.4
  • Diluted Normalized EPS
  • 12.78
  • Period
  • 2021
  • Total Revenue
  • 1333.2
  • Selling/ General/ Admin Expenses Total
  • 486.56
  • Depreciation/ Amortization
  • 37.81
  • Other Operating Expenses Total
  • 31.42
  • Total Operating Expense
  • 1039.09
  • Operating Income
  • 294.12
  • Net Income Before Taxes
  • 387.73
  • Net Income
  • 301.35
  • Diluted Normalized EPS
  • 17.79
  • Period
  • 2020
  • Total Revenue
  • 1344.19
  • Selling/ General/ Admin Expenses Total
  • 509.35
  • Depreciation/ Amortization
  • 37.46
  • Other Operating Expenses Total
  • 38.99
  • Total Operating Expense
  • 1063.77
  • Operating Income
  • 280.43
  • Net Income Before Taxes
  • 320.97
  • Net Income
  • 239.88
  • Diluted Normalized EPS
  • 13.17
  • Period
  • 2019
  • Total Revenue
  • 1090.7
  • Selling/ General/ Admin Expenses Total
  • 422.28
  • Depreciation/ Amortization
  • 33.24
  • Other Operating Expenses Total
  • 42.47
  • Total Operating Expense
  • 894.04
  • Operating Income
  • 196.66
  • Net Income Before Taxes
  • 236.64
  • Net Income
  • 169.79
  • Diluted Normalized EPS
  • 9.77
  • Period
  • 2018
  • Total Revenue
  • 1083.09
  • Selling/ General/ Admin Expenses Total
  • 403.71
  • Depreciation/ Amortization
  • 35.14
  • Other Operating Expenses Total
  • 36.92
  • Total Operating Expense
  • 885.19
  • Operating Income
  • 197.9
  • Net Income Before Taxes
  • 240.63
  • Net Income
  • 173.51
  • Diluted Normalized EPS
  • 9.73
  • Period
  • 2017
  • Total Revenue
  • 1050.98
  • Selling/ General/ Admin Expenses Total
  • 342.02
  • Depreciation/ Amortization
  • 34.62
  • Other Operating Expenses Total
  • 49.05
  • Total Operating Expense
  • 848.02
  • Operating Income
  • 202.96
  • Net Income Before Taxes
  • 251.83
  • Net Income
  • 188.53
  • Diluted Normalized EPS
  • 10.85
View detailed financials on Mint Genie

Forecast

Income Sheet (In Cr) Net Income Vs Revenue
Returns Metrics (In Cr) ROA Vs ROE

Technical

Moving Average SMA
  • 5 Day264.27
  • 10 Day270.02
  • 20 Day274.51
  • 50 Day266.33
  • 100 Day255.45
  • 300 Day269.63

Peers

  • Price
  • Ratio
  • Name
  • Latest Price
  • Change
  • % Change
  • 52W High
  • 52W Low
  • Mkt. Cap
  • FDC
  • 262.3
  • -0.55
  • -0.21
  • 366
  • 229.15
  • 4352.65
  • Hikal
  • 336.15
  • 6.8
  • 2.06
  • 636.1
  • 215.65
  • 4057.83

Corporate Actions

  • Board Meeting
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
  • Meeting Date
  • Purpose
  • 04-Aug-22
  • Quarterly Results
  • 25-May-22
  • Audited & Quarterly Results
  • 09-Feb-22
  • Quarterly Results
  • 11-Nov-21
  • Quarterly Results
  • 12-Aug-21
  • Quarterly Results
  • 26-May-21
  • Audited Results
  • 04-Feb-21
  • Quarterly Results

Company Profile

ABOUT FDC

  • Industry Biotechnology & Drugs
  • ISIN INE258B01022
  • BSE Code 531599
  • NSE Code FDC

FDC Limited is an India-based company, which is principally engaged in the business of pharmaceuticals. The Company manufactures and distributes its range of generics, formulations and active pharmaceuticals at its manufacturing plants. It also manufactures oral rehydration salts (ORS) and specialized formulations. It has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. It has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.

MANAGEMENT

  • Sanjay Jain Chief Financial Officer
  • Ameya Chandavarkar Chief Executive Officer - International Business, Executive Director
  • Varsharani Katre Compliance Officer, Company Secretary
  • Mohan Chandavarkar Managing Director, Executive Director
  • Nandan Chandavarkar Joint Managing Director, Executive Director
  • Ashok Chandavarkar Executive Director

Company Summary

FDC SUMMARY

FDC is trading 0.21% lower at Rs 262.30 as compared to its last closing price. FDC has been trading in the price range of 267.75 & 260.2. FDC has given -13.76% in this year & -5.58% in the last 5 days.

 

FDC has TTM P/E ratio 21.23 as compared to the sector P/E of 24.66. There are 1 analysts who have initiated coverage on FDC. There are 1 analysts who have given it a strong buy rating & 0 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.

 

The company posted a net profit of 70.74 Crores in its last quarter.

 

Listed peers of FDC include Jubilant Pharmova (1.12%), Glenmark Life Sciences (1.14%), FDC (-0.21%) etc.

FAQs about FDC

FDC is trading at 262.30 as on 30 Sep, 2022 3:29:55 PM. This is -0.21% lower as compared to its previous closing price of 262.85
The market capitalization of FDC is 4352.65 Cr as on 30 Sep, 2022 3:29:55 PM.
The average broker rating on FDC is Strong Buy. The breakup of analyst rating is given below -
  • 0 analysts have given a strong sell rating
  • 0 analysts have given a sell rating
  • 0 analysts have given a hold rating
  • 0 analysts have given a buy rating
  • 1 analysts have given a strong buy rating
The 52 wk high for FDC is 366.0 whereas the 52 wk low is 229.15
FDC can be analyzed on the following key metrics -
  • TTM P/E: 21.23
  • Sector P/E: 24.66
  • Dividend Yield: 0%
  • D/E ratio: -
FDC reported a net profit of 216.4 Cr in 2022.

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout